CLINICAL TRIALS PROFILE FOR LETERMOVIR
✉ Email this page to a colleague
All Clinical Trials for letermovir
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02137772 ↗ | Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2014-06-06 | The study evaluated the efficacy and safety of letermovir (MK-8228) for the prevention of clinically-significant CMV infection in adult, CMV-seropositive recipients of allogeneic hematopoietic stem cell transplant (HSCT). The hypothesis being tested was that MK-8228 is superior to placebo in the prevention of clinically-significant CMV infection through Week 24 post-transplant. |
| NCT03443869 ↗ | Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002) | Active, not recruiting | Merck Sharp & Dohme Corp. | Phase 3 | 2018-05-03 | The primary objective of this study is to evaluate the efficacy of letermovir (LET) versus valganciclovir (VGCV) in preventing CMV disease in adult kidney transplant recipients. The primary hypotheses are that LET is non-inferior to VGCV; and if non-inferiority is demonstrated, that LET is superior to VGCV, in preventing CMV disease through 52 weeks post-transplant. |
| NCT03728426 ↗ | Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection | Recruiting | Merck Sharp & Dohme Corp. | Phase 2 | 2019-01-11 | The trial will evaluate the safety and efficacy of letermovir antiviral treatment of active cytomegalovirus infection or cytomegalovirus disease in patients with infections that are refractory or resistant to available treatments or who are experiencing organ dysfunction that makes unsafe the use of available antiviral treatments. |
| NCT03728426 ↗ | Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection | Recruiting | Amy C. Sherman, MD | Phase 2 | 2019-01-11 | The trial will evaluate the safety and efficacy of letermovir antiviral treatment of active cytomegalovirus infection or cytomegalovirus disease in patients with infections that are refractory or resistant to available treatments or who are experiencing organ dysfunction that makes unsafe the use of available antiviral treatments. |
| NCT03728426 ↗ | Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection | Recruiting | Dana-Farber Cancer Institute | Phase 2 | 2019-01-11 | The trial will evaluate the safety and efficacy of letermovir antiviral treatment of active cytomegalovirus infection or cytomegalovirus disease in patients with infections that are refractory or resistant to available treatments or who are experiencing organ dysfunction that makes unsafe the use of available antiviral treatments. |
| NCT03930615 ↗ | Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040) | Active, not recruiting | Merck Sharp & Dohme Corp. | Phase 3 | 2019-06-21 | The purpose of this study is to evaluate the safety and efficacy of letermovir (LET) versus placebo when extended from 100 days to 200 days post-transplant in cytomegalovirus (CMV) seropositive participants who received an allogenic hematopoietic stem cell transplant (HSCT). It is hypothesized that LET is superior to placebo in the prevention of clinically-significant CMV infection when LET prophylaxis is extended from 100 to 200 days. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for letermovir
Condition Name
Clinical Trial Locations for letermovir
Trials by Country
Clinical Trial Progress for letermovir
Clinical Trial Phase
Clinical Trial Sponsors for letermovir
Sponsor Name
